199 related articles for article (PubMed ID: 24789797)
21. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial.
Sirima SB; Durier C; Kara L; Houard S; Gansane A; Loulergue P; Bahuaud M; Benhamouda N; Nebié I; Faber B; Remarque E; Launay O;
Vaccine; 2017 Oct; 35(45):6218-6227. PubMed ID: 28947345
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity of dimorphic and C-terminal fragments of Plasmodium falciparum MSP2 formulated with different adjuvants in mice.
Balam S; Jafarshad A; Servis C; Frank G; Reed S; Pink R; Druilhe P; Spertini F; Corradin G
Vaccine; 2016 Mar; 34(13):1566-1574. PubMed ID: 26874325
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
Lalitha PV; Biswas S; Pillai CR; Saxena RK
Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
[TBL] [Abstract][Full Text] [Related]
24. Comparative Immunogenicities of full-length Plasmodium falciparum merozoite surface protein 3 and a 24-kilodalton N-terminal fragment.
Imam M; Devi YS; Verma AK; Chauhan VS
Clin Vaccine Immunol; 2011 Aug; 18(8):1221-8. PubMed ID: 21632889
[TBL] [Abstract][Full Text] [Related]
25. IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice.
Schwenk R; DeBot M; Porter M; Nikki J; Rein L; Spaccapelo R; Crisanti A; Wightman PD; Ockenhouse CF; Dutta S
PLoS One; 2014; 9(10):e111020. PubMed ID: 25343487
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations.
Tamborrini M; Stoffel SA; Westerfeld N; Amacker M; Theisen M; Zurbriggen R; Pluschke G
Malar J; 2011 Dec; 10():359. PubMed ID: 22166048
[TBL] [Abstract][Full Text] [Related]
27. Fusion of two malaria vaccine candidate antigens enhances product yield, immunogenicity, and antibody-mediated inhibition of parasite growth in vitro.
Pan W; Huang D; Zhang Q; Qu L; Zhang D; Zhang X; Xue X; Qian F
J Immunol; 2004 May; 172(10):6167-74. PubMed ID: 15128804
[TBL] [Abstract][Full Text] [Related]
28. Rice-produced MSP142 of Plasmodium falciparum elicits antibodies that inhibit parasite growth in vitro.
Chen Q; Liang W; Qian F; Qian B; Cao J; Zhang D; Xu Y; Tang L
Parasite Immunol; 2016 Oct; 38(10):635-41. PubMed ID: 27493141
[TBL] [Abstract][Full Text] [Related]
29. Identification of adjuvants for clinical trials performed with Plasmodium falciparum AMA1 in rabbits.
Younis S; Faber BW; Kocken CHM; Remarque EJ
BMC Immunol; 2019 Jul; 20(1):25. PubMed ID: 31362695
[TBL] [Abstract][Full Text] [Related]
30. Pre-clinical assessment of novel multivalent MSP3 malaria vaccine constructs.
Bang G; Prieur E; Roussilhon C; Druilhe P
PLoS One; 2011; 6(12):e28165. PubMed ID: 22145028
[TBL] [Abstract][Full Text] [Related]
31. A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria.
Chang SP; Case SE; Gosnell WL; Hashimoto A; Kramer KJ; Tam LQ; Hashiro CQ; Nikaido CM; Gibson HL; Lee-Ng CT; Barr PJ; Yokota BT; Hut GS
Infect Immun; 1996 Jan; 64(1):253-61. PubMed ID: 8557348
[TBL] [Abstract][Full Text] [Related]
32. Regulation of antibody specificity to Plasmodium falciparum merozoite surface protein-1 by adjuvant and MHC haplotype.
Chang SP; Nikaido CM; Hashimoto AC; Hashiro CQ; Yokota BT; Hui GS
J Immunol; 1994 Apr; 152(7):3483-90. PubMed ID: 8144929
[TBL] [Abstract][Full Text] [Related]
33. Differential antibody recognition of four allelic variants of the merozoite surface protein-2 (MSP-2) of Plasmodium falciparum.
Tonhosolo R; Wunderlich G; Ferreira MU
J Eukaryot Microbiol; 2001; 48(5):556-64. PubMed ID: 11596920
[TBL] [Abstract][Full Text] [Related]
34. Transdermal immunization of P. falciparum surface antigen (MSP-119) via elastic liposomes confers robust immunogenicity.
Tyagi RK; Garg NK; Dalai SK; Awasthi A
Hum Vaccin Immunother; 2016 Apr; 12(4):990-2. PubMed ID: 26810033
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of a Plasmodium-Specific Carrier Protein To Enhance Production of Recombinant
Parzych EM; Miura K; Ramanathan A; Long CA; Burns JM
Infect Immun; 2018 Jan; 86(1):. PubMed ID: 28993460
[TBL] [Abstract][Full Text] [Related]
36. Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01.
Otsyula N; Angov E; Bergmann-Leitner E; Koech M; Khan F; Bennett J; Otieno L; Cummings J; Andagalu B; Tosh D; Waitumbi J; Richie N; Shi M; Miller L; Otieno W; Otieno GA; Ware L; House B; Godeaux O; Dubois MC; Ogutu B; Ballou WR; Soisson L; Diggs C; Cohen J; Polhemus M; Heppner DG; Ockenhouse CF; Spring MD
Malar J; 2013 Jan; 12():29. PubMed ID: 23342996
[TBL] [Abstract][Full Text] [Related]
37. Alga-produced malaria transmission-blocking vaccine candidate Pfs25 formulated with a human use-compatible potent adjuvant induces high-affinity antibodies that block Plasmodium falciparum infection of mosquitoes.
Patra KP; Li F; Carter D; Gregory JA; Baga S; Reed SG; Mayfield SP; Vinetz JM
Infect Immun; 2015 May; 83(5):1799-808. PubMed ID: 25690099
[TBL] [Abstract][Full Text] [Related]
38. Antibody responses to a novel Plasmodium falciparum merozoite surface protein vaccine correlate with protection against experimental malaria infection in Aotus monkeys.
Cavanagh DR; Kocken CH; White JH; Cowan GJ; Samuel K; Dubbeld MA; Voorberg-van der Wel A; Thomas AW; McBride JS; Arnot DE
PLoS One; 2014; 9(1):e83704. PubMed ID: 24421900
[TBL] [Abstract][Full Text] [Related]
39. Identification of cultivation condition to produce correctly folded form of a malaria vaccine based on Plasmodium falciparum merozoite surface protein-1 in Escherichia coli.
Mazumdar S; Sachdeva S; Chauhan VS; Yazdani SS
Bioprocess Biosyst Eng; 2010 Aug; 33(6):719-30. PubMed ID: 19921275
[TBL] [Abstract][Full Text] [Related]
40. Fine specificity of serum antibodies to Plasmodium falciparum merozoite surface protein, PfMSP-1(19), predicts protection from malaria infection and high-density parasitemia.
Okech BA; Corran PH; Todd J; Joynson-Hicks A; Uthaipibull C; Egwang TG; Holder AA; Riley EM
Infect Immun; 2004 Mar; 72(3):1557-67. PubMed ID: 14977962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
